Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1135

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1135
---
. It has never generated any revenue
relating to its cancer diagnostics AI platform. Renovaro Cube’s short operating history makes any assessment of its current business
or future success and viability subject to significant uncertainty. BioSymetrics does have a history of deployment of a commercial AI-based
biotechnology platform and has had previous revenue generation, however the same risk regarding future performance applies. We expect
to encounter risks and difficulties, including those frequently experienced by early-stage companies in rapidly evolving fields.
If we do not address these risks and difficulties successfully, our business will suffer.

23

Renovaro
Cube and BioSymetrics have a history of net losses and anticipates that they may continue to incur net losses for the foreseeable future.

Grace
Systems (Renovaro Cube’s predecessor) has primarily incurred net losses since its inception in 2013 and has never generated any
revenue relating to its cancer diagnostics AI platform. Renovaro Cube anticipates that it may continue to incur primarily net losses in
the foreseeable future. Similarly, while BioSymetrics has a history of revenue generation since its inception in 2017, these revenues
have been inconsistent. Both Renovaro Cube and BioSymetrics have invested significant financial resources in research and development
activities, including to develop their technologies and investigational products. The amount of each company’s future net losses
will depend, in part, on the level of future expenditures and their ability to generate revenue following the commercialization of their
AI platform. Moreover, net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison
of results of operations may not be a good indication of future performance.

Renovaro
Cube and BioSymetrics expect to continue to incur significant expenses and operating losses for the foreseeable future if, and as, they:

    ●
    attract, hire, and retain qualified personnel;

    ●
    continue their research and development activities;

    ●
    initiate and conduct additional clinical validation to support the development and commercialization of products;

    ●
    expands their technological and operating capabilities and introduce laboratory capacity;

    ●
    seek regulatory approvals and any other marketing authorizations or clearances that may be necessary or desired for their products;

    ●
    establish sales, marketing and distribution infrastructure to commercialize products;

    ●
    acquire or in-license additional intellectual property and technologies;

    ●
    make milestone, royalty, or other payments due under any license or collaboration